ATE272406T1 - Prognose von ptp lar vermittelten krankheiten - Google Patents
Prognose von ptp lar vermittelten krankheitenInfo
- Publication number
- ATE272406T1 ATE272406T1 AT00921845T AT00921845T ATE272406T1 AT E272406 T1 ATE272406 T1 AT E272406T1 AT 00921845 T AT00921845 T AT 00921845T AT 00921845 T AT00921845 T AT 00921845T AT E272406 T1 ATE272406 T1 AT E272406T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- ptp lar
- prediction
- mediated diseases
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12867399P | 1999-04-09 | 1999-04-09 | |
PCT/US2000/009274 WO2000061180A2 (en) | 1999-04-09 | 2000-04-06 | Products and methods for treating ptp lar related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE272406T1 true ATE272406T1 (de) | 2004-08-15 |
Family
ID=22436431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00921845T ATE272406T1 (de) | 1999-04-09 | 2000-04-06 | Prognose von ptp lar vermittelten krankheiten |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090074722A1 (de) |
EP (1) | EP1169054B1 (de) |
JP (1) | JP2002541214A (de) |
AT (1) | ATE272406T1 (de) |
AU (1) | AU4210900A (de) |
CA (1) | CA2365945A1 (de) |
DE (1) | DE60012718T2 (de) |
PT (1) | PT1169054E (de) |
WO (1) | WO2000061180A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2279749B1 (de) * | 2004-10-12 | 2015-06-10 | Crucell Holland B.V. | Bindungsmoleküle zur detektion von aml |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6112896A (en) * | 1995-06-07 | 1996-12-30 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders |
NZ510991A (en) * | 1997-03-05 | 2002-11-26 | Sugen Inc | Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders |
EP1080068A1 (de) * | 1998-03-12 | 2001-03-07 | Novo Nordisk A/S | Modulatoren der protein-tyrosin-phosphatasen |
-
2000
- 2000-04-06 AT AT00921845T patent/ATE272406T1/de not_active IP Right Cessation
- 2000-04-06 PT PT00921845T patent/PT1169054E/pt unknown
- 2000-04-06 AU AU42109/00A patent/AU4210900A/en not_active Abandoned
- 2000-04-06 EP EP00921845A patent/EP1169054B1/de not_active Expired - Lifetime
- 2000-04-06 JP JP2000610512A patent/JP2002541214A/ja active Pending
- 2000-04-06 DE DE60012718T patent/DE60012718T2/de not_active Expired - Fee Related
- 2000-04-06 CA CA002365945A patent/CA2365945A1/en not_active Abandoned
- 2000-04-06 WO PCT/US2000/009274 patent/WO2000061180A2/en active IP Right Grant
-
2008
- 2008-02-26 US US12/071,815 patent/US20090074722A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002541214A (ja) | 2002-12-03 |
WO2000061180A3 (en) | 2001-06-28 |
EP1169054A2 (de) | 2002-01-09 |
EP1169054B1 (de) | 2004-08-04 |
PT1169054E (pt) | 2004-11-30 |
WO2000061180A2 (en) | 2000-10-19 |
DE60012718D1 (de) | 2004-09-09 |
AU4210900A (en) | 2000-11-14 |
US20090074722A1 (en) | 2009-03-19 |
CA2365945A1 (en) | 2000-10-19 |
DE60012718T2 (de) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
EA200001258A1 (ru) | Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
DE60015070D1 (de) | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache | |
DE69927823D1 (de) | Hydrogel für die therapeutische behandlung von aneurysmas | |
BR0207811A (pt) | Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças | |
DE69722681D1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen | |
ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DE59704933D1 (de) | Verwendung von PHMB zur Behandlung von Tumorerkrankungen | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
DE59900286D1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
ATE272406T1 (de) | Prognose von ptp lar vermittelten krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1169054 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |